CC-122
Drug
Celgene Corporation
Total Payments
$9.0M
Transactions
179
Doctors
29
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $2.6M | 41 | 4 |
| 2018 | $3.8M | 70 | 25 |
| 2017 | $2.6M | 68 | 12 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.0M | 177 | 100.0% |
| Food and Beverage | $34.60 | 2 | 0.0% |
Payments by Type
Research
$9.0M
177 transactions
General
$34.60
2 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CC-122-CLL-001 - Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations CC-122 AND Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocyti | Celgene Corporation | $2.0M | 4 |
| CC-122-CLL-001 | Celgene Corporation | $1.1M | 1 |
| Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations CC-122 AND Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CC-122-CLL-001) | Celgene Corporation | $1.0M | 0 |
| CC-122-DLBCL-001 - A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | Celgene Corporation | $979,243 | 17 |
| CC-122-DLBCL-001 | Celgene Corporation | $707,174 | 9 |
| A Phase 1/2 Open-Label Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor Risk (IPI>=3) Diffuse Large B-Cell Lymphoma (CC-122-DLBCL-002) | Celgene Corporation | $528,336 | 0 |
| CC-122-ST-001 - Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | Celgene Corporation | $500,697 | 3 |
| CC-122-ST-001 | Celgene Corporation | $469,782 | 0 |
| A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma (CC-122-DLBCL-001) | Celgene Corporation | $361,856 | 0 |
| A Phase II Biomarker Trial of CC-122 in Combination with Nivolumab in Advanced Melanoma (CC-122-CL-MEL-PI-13238) | Celgene Corporation | $323,063 | 0 |
| Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma (CC-122-ST-001) | Celgene Corporation | $309,593 | 3 |
| CC-122-DLBCL-002 - A Phase 1/2 Open-Label Multicenter Study of Avadomide (CC-122) in Combination With R-CHOP-21 for Previously Untreated Poor Risk (IPI>=3) Diffuse Large B-Cell Lymphoma | Celgene Corporation | $166,863 | 0 |
| CC-122-HCC-001 | Celgene Corporation | $100,154 | 0 |
| CC-122-HCC-002 | Celgene Corporation | $98,699 | 0 |
| CC-122-HCC-002 - A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellull | Celgene Corporation | $92,269 | 1 |
| CC-122-CP-005 - A Phase 1, Open-label, Single-dose Study to Assess the Pharmacokinetics (PK) of CC-122 in Subjects with Mild, Moderate and Severe Renal Impairment | Celgene Corporation | $81,902 | 0 |
| CC-122-CP-005 | Celgene Corporation | $57,950 | 0 |
| A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure (CC-122-HCC-002) | Celgene Corporation | $24,827 | 0 |
| Ph 1b Avadomide DLBCL R/R (PO_Number) | Celgene Corporation | $7,860 | 0 |
| CC-122-ST-001 CC-122-DLBCL-001 | Celgene Corporation | $2,976 | 2 |
Top Doctors Receiving Payments for CC-122
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $8.9M | 137 |
| , MD | Internal Medicine | San Antonio, TX | $7,237 | 4 |
| , MD | Medical Oncology | Tampa, FL | $5,618 | 2 |
| , M.D | Hematology & Oncology | Madison, WI | $4,536 | 2 |
| , M.D | Hematology | Houston, TX | $4,536 | 2 |
| , M.D | Hematology & Oncology | Nashville, TN | $4,536 | 2 |
| , M.D | Hematology | Rochester, MN | $4,536 | 2 |
| Mecide Gharibo | Medical Oncology | New Brunswick, NJ | $4,354 | 2 |
| , M.D | Medical Oncology | Memphis, TN | $3,012 | 2 |
| , M.D | Hematology & Oncology | New Haven, CT | $3,012 | 2 |
| , MD | Medical Oncology | Palo Alto, CA | $3,012 | 2 |
| , MD | Hematology | Chicago, IL | $3,012 | 2 |
| , M.D | Hematology & Oncology | San Antonio, TX | $2,866 | 1 |
| , M.D | Hematology & Oncology | Nashville, TN | $2,866 | 1 |
| , M.D | Hematology & Oncology | Rochester, MN | $2,866 | 1 |
| , M.D | Medical Oncology | Santa Barbara, CA | $1,524 | 1 |
| Leonard Klein | Hematology & Oncology | Niles, IL | $1,524 | 1 |
| , MD | Hematology & Oncology | Boulder, CO | $1,524 | 1 |
| , MD | Internal Medicine | Los Angeles, CA | $1,524 | 1 |
| Sonali Smith | Hematology & Oncology | Chicago, IL | $1,082 | 1 |
| , MD | Medical Oncology | Saint Louis, MO | $1,082 | 1 |
| , M.D | Medical Oncology | Boston, MA | $1,082 | 1 |
| , M.D | Hematology & Oncology | New York, NY | $1,082 | 1 |
| , MD | Internal Medicine | New York, NY | $1,082 | 1 |
| , MD PHD | Internal Medicine | Boston, MA | $442.00 | 1 |
Ad
Manufacturing Companies
- Celgene Corporation $9.0M
Product Information
- Type Drug
- Total Payments $9.0M
- Total Doctors 29
- Transactions 179
About CC-122
CC-122 is a drug associated with $9.0M in payments to 29 healthcare providers, recorded across 179 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $2.6M was paid across 41 transactions to 4 doctors.
The most common payment nature for CC-122 is "Unspecified" ($9.0M, 100.0% of total).
CC-122 is associated with 20 research studies, including "CC-122-CLL-001 - Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations CC-122 AND Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocyti" ($2.0M).